{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:02:20Z","timestamp":1781650940817,"version":"3.54.5"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Xinglin Scholars Research Promotion Project of Chengdu University of TCM","award":["YYZX20180027"],"award-info":[{"award-number":["YYZX20180027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10067-020-05429-1","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T03:03:00Z","timestamp":1603767780000},"page":"2143-2154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Biologic therapy in Sj\u00f6gren\u2019s syndrome"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-3816","authenticated-orcid":false,"given":"Qin","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"5429_CR1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1503\/cmaj.122037","volume":"186","author":"CP Mavragani","year":"2014","unstructured":"Mavragani CP, Moutsopoulos HM (2014) Sj\u00f6gren\u2019s syndrome review. Can Med Assoc J 186:579\u2013586","journal-title":"Can Med Assoc J"},{"key":"5429_CR2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.7861\/clinmedicine.14-2-157","volume":"14","author":"A Esha","year":"2014","unstructured":"Esha A, Cristina G-P, Juan MP-F et al (2014) A retrospective study of long-term outcomes in 152 patients with primary Sj\u00f6gren\u2019s syndrome: 25-year experience. Clin Med 14:157\u2013164","journal-title":"Clin Med"},{"key":"5429_CR3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/1529-0131(200008)43:8<1756::AID-ANR12>3.0.CO;2-H","volume":"43","author":"M Azuma","year":"2000","unstructured":"Azuma M, Aota K, Tamatani T, Motegi K, Yamashita T, Harada K, Hayashi Y, Sato M (2000) Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production by the introduction of a super-repressor form of inhibitor of nuclear factor kappa B alpha complementary DNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sj\u00f6gren\u2019s syndrome salivary glands. Arthritis Rheum 43:1756\u20131767","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5429_CR4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Pu\u00e9chal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J (2004) Inefficacy of infliximab in primary Sj\u00f6gren\u2019s syndrome: results of the randomized, controlled trial of remicade in primary Sj\u00f6gren\u2019s syndrome(TRIPSS). Arthritis Rheum 50(4):1270\u20131276","journal-title":"Arthritis Rheum"},{"issue":"7","key":"5429_CR5","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"V Sankar","year":"2004","unstructured":"Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR (2004) Etanercept in Sj\u00f6gren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50(7):2240\u20132245","journal-title":"Arthritis Rheum"},{"issue":"12","key":"5429_CR6","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/art.23062","volume":"56","author":"CP Mavragani","year":"2007","unstructured":"Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK (2007) Augmented interferon-alpha pathway activation in patients with Sj\u00f6gren\u2019s syndrome treated with etanercept. Arthritis Rheum 56(12):3995\u20134004","journal-title":"Arthritis Rheum"},{"key":"5429_CR7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/acr.22968","volume":"69","author":"SE Carsons","year":"2017","unstructured":"Carsons SE, Vivino FB, Parke A, Carteron N, Sankar V, Brasington R, Brennan MT, Ehlers W, Fox R, Scofield H, Hammitt KM, Birnbaum J, Kassan S, Mandel S (2017) Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren\u2019s syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain. Arthritis Care Res 69:517\u2013527","journal-title":"Arthritis Care Res"},{"key":"5429_CR8","first-page":"27","volume":"98","author":"Y Ishikawa","year":"2019","unstructured":"Ishikawa Y, Hattori K, Ishikawa J, Fujiwara M, Kita Y et al (2019) Refractory Sj\u00f6gren\u2019s syndrome myelopathy successfully treated with subcutaneous tocilizumab. Medicine 98:27","journal-title":"Medicine"},{"key":"5429_CR9","first-page":"294","volume":"26","author":"T Komai","year":"2013","unstructured":"Komai T, Shoda H, Yamaguchi K, Sakurai K, Shibuya M, Kubo K et al (2013) Neuromyelitis optica spectrum disorder complicated with Sj\u00f6gren\u2019s syndrome successfully treated with tocilizumab: a case report. Mordern Rheumatol 26:294\u2013296","journal-title":"Mordern Rheumatol"},{"key":"5429_CR10","first-page":"2014","volume":"14","author":"A Justet","year":"2015","unstructured":"Justet A, Ottaviani S, Dieud\u00e9 P, Taill\u00e9 C (2015) Tocilizumab for refractory organising pneumonia associated with Sj\u00f6gren\u2019s disease. BMJ Case Rep 14:2014\u20132016","journal-title":"BMJ Case Rep"},{"key":"5429_CR11","doi-asserted-by":"publisher","first-page":"key438","DOI":"10.1093\/rheumatology\/key438","volume":"5","author":"SLM Blokland","year":"2019","unstructured":"Blokland SLM, Flessa CM, van Roon JAG, Mavragani CP (2019) Emerging roles for chemokines and cytokines as orchestrators of immunopathology in Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 5:key438. https:\/\/doi.org\/10.1093\/rheumatology\/key438 Online ahead of print","journal-title":"Rheumatology (Oxford)"},{"key":"5429_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-9255-4-5","volume":"4","author":"MF Lister","year":"2007","unstructured":"Lister MF, Sharkey J, Sawatzky DA, Hodgkiss JP, Davidson DJ, Rossi AG, Finlayson K (2007) The role of the purinergic P2X7receptor in inflammation. J Inflamm 4:1\u201314. https:\/\/doi.org\/10.1186\/1476-9255-4-5","journal-title":"J Inflamm"},{"key":"5429_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","volume":"165","author":"VAK Rathinam","year":"2016","unstructured":"Rathinam VAK, Fitzgerald KA (2016) Inflammasome complexes: emerging mechanisms and effector functions. Cell. 165:792\u2013800. https:\/\/doi.org\/10.1016\/j.cell.2016.03.046","journal-title":"Cell."},{"key":"5429_CR14","first-page":"1957","volume":"19","author":"T Vijmasi","year":"2013","unstructured":"Vijmasi T, Chen FYT, Chen YT, Gallup M, McNamara N (2013) Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis 19:1957\u201365.eCollection 2013","journal-title":"Mol Vis"},{"issue":"1","key":"5429_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030123","volume":"7","author":"KB Norheim","year":"2012","unstructured":"Norheim KB, Harboe E, G\u00f8ransson LG, Omdal R (2012) Interleukin-1 inhibition and fatigue in primary Sj\u00f6gren\u2019s syndrome-a double blind, randomised clinical trial. PLoS One 7(1):e30123. https:\/\/doi.org\/10.1371\/journal.pone.0030123","journal-title":"PLoS One"},{"issue":"3","key":"5429_CR16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3315\/jdcr.2015.1207","volume":"9","author":"MS Chimenti","year":"2015","unstructured":"Chimenti MS, Talamonti M, Novelli L, Teoli M, Galluzzo M, Triggianese P, Perricone R (2015) Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sj\u00f6gren syndrome. Report of two cases and review of literature. J Dermatol Case Rep 9(3):71\u201375","journal-title":"J Dermatol Case Rep"},{"key":"5429_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM197907053010102","volume":"301","author":"JJ Hooks","year":"1979","unstructured":"Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL (1979) Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 301:5\u20138. https:\/\/doi.org\/10.1056\/NEJM197907053010102","journal-title":"N Engl J Med"},{"key":"5429_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jaut.2015.07.002","volume":"63","author":"A Nezos","year":"2015","unstructured":"Nezos A, Gravani F, Tassidou A, Kapsogeorgou EK, Voulgarelis M, Koutsilieris M, Crow MK, Mavragani CP (2015) Type I and II interferon signatures in Sj\u00f6gren\u2019s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sj\u00f6gren\u2019s related lymphomagenesis. J Autoimmun 63:47\u201358. https:\/\/doi.org\/10.1016\/j.jaut.2015.07.002","journal-title":"J Autoimmun"},{"key":"5429_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/1744666X.2014.876364","volume":"10","author":"Z Brkic","year":"2014","unstructured":"Brkic Z, Versnel MA (2014) Type I IFN signature in primary Sj\u00f6gren\u2019s syndrome patients. Expert Rev Clin Immunol 10:457\u2013467. https:\/\/doi.org\/10.1586\/1744666X.2014.876364","journal-title":"Expert Rev Clin Immunol"},{"key":"5429_CR20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","volume":"72","author":"Z Brkic","year":"2013","unstructured":"Brkic Z, Maria NI, Van Helden-Meeuwsen CG, Van De Merwe JP, Van Daele PL, Dalm VA et al (2013) Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren\u2019s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 72:728\u2013735. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201381","journal-title":"Ann Rheum Dis"},{"key":"5429_CR21","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/art.39204","volume":"67","author":"JC Hall","year":"2015","unstructured":"Hall JC, Baer AN, Shah AA, Criswell LA, Shiboski CH, Rosen A, Casciola-Rosen L (2015) Molecular subsetting of interferon pathways in Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 67:2437\u20132446. https:\/\/doi.org\/10.1002\/art.39204","journal-title":"Arthritis Rheum"},{"key":"5429_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fimmu.2013.00142","volume":"4","author":"CQ Nguyen","year":"2013","unstructured":"Nguyen CQ, Peck AB (2013) The interferon-signature of Sj\u00f6gren\u2019s syndrome: how unique biomarkers can identify underlying inflammatory and immunopathological mechanisms of specific diseases. Front Immunol 4:142","journal-title":"Front Immunol"},{"key":"5429_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2019-eular.3098","volume":"177","author":"B Fisher","year":"2019","unstructured":"Fisher B, Barone F, Jobling K, Gallagher P, Macrae V, Filby A et al (2019) OP0202 effect of rslv-132 on fatigue in patients with primary Sj\u00f6gren\u2019s syndrome-results of a phase II randomised, double-blind, placebo-controlled, proof of concept study. Ann Rheum Dis 177:1\u2013177. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.3098","journal-title":"Ann Rheum Dis"},{"key":"5429_CR24","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","volume":"64","author":"JM McBride","year":"2012","unstructured":"McBride JM, Jiang J, Abbas AR (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64:3666\u20133676","journal-title":"Arthritis Rheum"},{"key":"5429_CR25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1089\/107999099313497","volume":"19","author":"JA Ship","year":"1999","unstructured":"Ship JA, Fox PC, Michalek JE (1999) Treatment of primary Sj\u00f6gren\u2019s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interf Cytokine Res 19:943\u2013951","journal-title":"J Interf Cytokine Res"},{"key":"5429_CR26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","volume":"49","author":"MJ Cummins","year":"2003","unstructured":"Cummins MJ, Papas A, Kammer GM, Fox PC (2003) Treatment of primary Sj\u00f6gren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 49:585\u2013593","journal-title":"Arthritis Rheum"},{"key":"5429_CR27","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1073\/pnas.0510837103","volume":"103","author":"JE Gottenberg","year":"2006","unstructured":"Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X (2006) Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren\u2019s syndrome. Proc Natl Acad Sci U S A 103:2770\u20132775. https:\/\/doi.org\/10.1073\/pnas.0510837103","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"5429_CR28","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/art.39214","volume":"67","author":"E Theander","year":"2015","unstructured":"Theander E, Jonsson R, Sj\u00f6str\u00f6m B, Brokstad K, Olsson P, Henriksson G (2015) Prediction of Sj\u00f6gren\u2019s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. Arthritis Rheum 67(9):2427\u20132436. https:\/\/doi.org\/10.1002\/art.39214","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5429_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.semarthrit.2012.07.003","volume":"42","author":"AP Risselada","year":"2013","unstructured":"Risselada AP, Looije MF, Kruize AA, Bijlsma JWJ, van Roon JAG (2013) The role of ectopic germinal centers in the immunopathology of primary Sj\u00f6gren\u2019s syndrome: a systematic review. Semin Arthritis Rheum 42(4):368\u2013376. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.07.003","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"5429_CR30","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/art.39518","volume":"68","author":"G Nocturne","year":"2016","unstructured":"Nocturne G, Virone A, Hachulla E, Cornec D, Bienvenu B, Marcelli C et al (2016) Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 68(4):977\u2013985. https:\/\/doi.org\/10.1002\/art.39518","journal-title":"Arthritis Rheum"},{"key":"5429_CR31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4049\/jimmunol.135.2.973","volume":"135","author":"TF Tedder","year":"1985","unstructured":"Tedder TF, Boyd AW, Freedman AS et al (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135:973\u2013979","journal-title":"J Immunol"},{"key":"5429_CR32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Rou\u00e9 IQ, Cochener B, Youinou P, Saraux A (2007) Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 57:310\u2013317","journal-title":"Arthritis Rheum"},{"key":"5429_CR33","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K et al (2005) Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum 52:2740\u20132750","journal-title":"Arthritis Rheum"},{"key":"5429_CR34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian A, Ravaud P, Hatron PY, Larroche C, Leone J, Gombert B, Hamidou M, Cantagrel A, Marcelli C, Rist S, Breban M, Launay D, Fain O, Gottenberg JE, Mariette X (2012) Efficacy of rituximab in primary Sj\u00f6gren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 71:84\u201387","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5429_CR35","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A, Spijkervet FKL, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CGM, Bootsma H (2010) Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(4):960\u2013968","journal-title":"Arthritis Rheum"},{"issue":"11","key":"5429_CR36","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P (2008) Reduction of fatigue in Sj\u00f6gren\u2019s syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rherm Dis 67(11):1541\u20131544","journal-title":"Ann Rherm Dis"},{"issue":"3","key":"5429_CR37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X (2007) Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 66(3):351\u2013357","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"5429_CR38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Pu\u00e9chal X, le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A (2014) Treatment of primary Sj\u00f6gren\u2019s syndrome with rituximab: a randomized trial. Ann Intern Med 160(4):233\u2013242","journal-title":"Ann Intern Med"},{"issue":"3","key":"5429_CR39","volume":"11","author":"FB Souza","year":"2016","unstructured":"Souza FB, Porf\u00edrio GJ, Andriolo BN et al (2016) Rituximab effectiveness and safety for treating primary Sj\u00f6gren\u2019s syndrome (pSS): systematic review and meta-analysis. PLoS One 11(3):e0150749","journal-title":"PLoS One"},{"issue":"1","key":"5429_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/08830185.2016.1276903","volume":"36","author":"E Samy","year":"2017","unstructured":"Samy E, Wax S, Huard B, Hess H, Schneider P (2017) Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol 36(1):3\u201319. https:\/\/doi.org\/10.1080\/08830185.2016.1276903","journal-title":"Int Rev Immunol"},{"key":"5429_CR41","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","volume":"74","author":"X Mariette","year":"2015","unstructured":"Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, de Vita S (2015) Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 74:526\u2013531. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203991","journal-title":"Ann Rheum Dis"},{"key":"5429_CR42","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/rheumatology\/kev257","volume":"54","author":"S De Vita","year":"2015","unstructured":"De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Mariette X et al (2015) Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study. Rheumatology (UK) 54:2249\u20132256. https:\/\/doi.org\/10.1093\/rheumatology\/kev257","journal-title":"Rheumatology (UK)"},{"issue":"4","key":"5429_CR43","first-page":"490","volume":"32","author":"S De Vita","year":"2014","unstructured":"De Vita S, Quartuccio L, Salvin S, Picco L, Scott CA, Rupolo M et al (2014) Sequential therapy with belimumab followed by rituximab in Sj\u00f6gren\u2019s syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol 32(4):490\u2013494","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5429_CR44","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin M-A, Simonett C, Mooney L, H\u00fcser A, Gram H, Wagner FD, Oliver SJ (2019) Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced. Antibody-Dependent Cellular Cytotoxicity Ann Rheum Dis 78(5):641\u2013647. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214720","journal-title":"Antibody-Dependent Cellular Cytotoxicity Ann Rheum Dis"},{"issue":"6","key":"5429_CR45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0961203309102803","volume":"18","author":"C Pena-Rossi","year":"2009","unstructured":"Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, Saunders H, Hill J, Nestorov I (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmaco-dynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 18(6):547\u2013555","journal-title":"Lupus."},{"issue":"7","key":"5429_CR46","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","volume":"63","author":"RF vanVollenhoven","year":"2011","unstructured":"vanVollenhoven RF, Kinnman N, Vincent E et al (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthritis Rheum 63(7):1782\u20131792","journal-title":"Arthritis Rheum"},{"key":"5429_CR47","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1074-7613(00)80270-8","volume":"5","author":"S Sato","year":"1996","unstructured":"Sato S, Miller AS, Inaoki M, Bock CB, Jansen PJ, Tang MLK, Tedder TF (1996) CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity. 5:551\u2013562. https:\/\/doi.org\/10.1016\/S1074-7613(00)80270-8","journal-title":"Immunity."},{"key":"5429_CR48","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1158\/1078-0432.CCR-04-0294","volume":"10","author":"JP Leonard","year":"2004","unstructured":"Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM (2004) Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin\u2019s lymphoma: phase I\/II clinical trial results. Clin Cancer Res 10:5327\u20135334","journal-title":"Clin Cancer Res"},{"key":"5429_CR49","doi-asserted-by":"publisher","unstructured":"Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF (2006) CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J Immunol 177:3063\u20133073. https:\/\/doi.org\/10.4049\/jimmunol.177.5.3063","DOI":"10.4049\/jimmunol.177.5.3063"},{"key":"5429_CR50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acr.22694","volume":"68","author":"DJ Wallace","year":"2016","unstructured":"Wallace DJ, Hobbs K, Clowse MEB, Petri M, Strand V, Pike M, Merrill JT, Leszczy\u0144ski P, Neuwelt CM, Jeka S, Houssiau F, Keiserman M, Ordi-Ros J, Bongardt S, Kilgallen B, Galateanu C, Kalunian K, Furie R, Gordon C (2016) Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study. Arthritis Care Res 68:534\u2013543. https:\/\/doi.org\/10.1002\/acr.22694","journal-title":"Arthritis Care Res"},{"key":"5429_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD, Tant L, Burmester GR, Teoh NKW, Wegener WA, Goldenberg DM (2006) Epratuzumab (humanised anti-CD22 antibody) in primary Sj\u00f6gren\u2019s syndrome: an open-label phase I\/II study. Arthritis Res Ther 8:1\u201311. https:\/\/doi.org\/10.1186\/ar2018","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"5429_CR52","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jaci.2016.01.024","volume":"137","author":"M Mingueneau","year":"2016","unstructured":"Mingueneau M, Boudaoud S, Haskett S, Reynolds TL, Nocturne G, Norton E et al (2016) Cytometry by time-of-flight immunophenotyping identifies a blood Sj\u00f6gren\u2019s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 137(6):1809\u20131821.e12. https:\/\/doi.org\/10.1016\/j.jaci.2016.01.024","journal-title":"J Allergy Clin Immunol"},{"key":"5429_CR53","first-page":"362","volume":"56","author":"M Jasiek","year":"2017","unstructured":"Jasiek M, Karras A, Guern VL, Krastinova E, Mesbah R, Faguer S et al (2017) A multicentre study of 95 biopsy-proven cases of renal disease in primary Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 56:362\u2013370","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5429_CR54","doi-asserted-by":"crossref","first-page":"R2","DOI":"10.1186\/ar3220","volume":"13","author":"EA Szyszko","year":"2011","unstructured":"Szyszko EA, Brokstad KA, Oijordsbakken G, Jonsson MV, Jonsson R, Skarstein K (2011) Salivary glands of primary Sj\u00f6gren\u2019s syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther 13(1):R2","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"5429_CR55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cei.12058","volume":"172","author":"LA Aqrawi","year":"2013","unstructured":"Aqrawi LA, Skarstein K, Oijordsbakken G, Brokstad KA (2013) Ro52-and Ro60-specific B cell pattern in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome. Clin Exp Immunol 172(2):228\u2013237","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"5429_CR56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/RHU.0000000000000210","volume":"21","author":"J Jakez-Ocampo","year":"2015","unstructured":"Jakez-Ocampo J, Atisha-Fregoso Y, Llorente L (2015) Refractory primary Sj\u00f6gren\u2019s syndrome successfully treated with bortezomib. J Clin Rheumatol 21(1):31\u201332","journal-title":"J Clin Rheumatol"},{"key":"5429_CR57","first-page":"43","volume":"97","author":"R Sun","year":"2018","unstructured":"Sun R, Weiying G, Ma Y, Wang J, Min W (2018) Relapsed\/refractory acquired thrombotic thrombocytopenic purpura in a patient with Sj\u00f6gren\u2019s syndrome. Medicine 97:43","journal-title":"Medicine"},{"key":"5429_CR58","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/blood.V128.22.4195.4195","volume":"128","author":"T Phillips","year":"2016","unstructured":"Phillips T, Ramchandren R, Wertheim MS, Gutierrez ME, Edenfield WJ, Dawkins F, DeMarini DJ, Zhou L, Yeleswaram S, Newton RC, Chen X, Forero-Torres A (2016) An ongoing open-label phase 1\/2 study of INCB050465, a selective PI3K\u03b4 inhibitor, in patients with previously treated B-cell malignancies. Blood. 128:4195","journal-title":"Blood."},{"key":"5429_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/annrheumdis-2017-212619","volume":"78","author":"S Nayar","year":"2019","unstructured":"Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S et al (2019) Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 78:249\u2013260. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212619","journal-title":"Ann Rheum Dis"},{"key":"5429_CR60","doi-asserted-by":"publisher","first-page":"58","DOI":"10.4049\/jimmunol.1600208","volume":"197","author":"B Odilia","year":"2016","unstructured":"Odilia B, Corneth J, de Bruijn MJW, Rip J, Asmawidjaja PS, Kil LP, Hendriks RW (2016) Enhanced expression of Bruton\u2019s tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis. J Immunol 197:58\u201367. https:\/\/doi.org\/10.4049\/jimmunol.1600208http:\/\/www.jimmunol.org\/content\/197\/1\/58","journal-title":"J Immunol"},{"issue":"6","key":"5429_CR61","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/art.40059","volume":"69","author":"OBJ Corneth","year":"2017","unstructured":"Corneth OBJ, Verstappen GMP, Paulissen SMJ, de Bruijn MJW, Rip J, Lukkes M et al (2017) Enhanced Bruton\u2019s tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. Arthritis Rheum 69(6):1313\u20131324. https:\/\/doi.org\/10.1002\/art.40059","journal-title":"Arthritis Rheum"},{"key":"5429_CR62","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/cas.13983","volume":"110","author":"W Munakata","year":"2019","unstructured":"Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K (2019) Phase I study of tirabrutinib (ONO-4059\/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci 110:1686\u20131694. https:\/\/doi.org\/10.1111\/cas.13983","journal-title":"Cancer Sci"},{"key":"5429_CR63","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/1744666X.2014.878650","volume":"10","author":"MR Millen","year":"2014","unstructured":"Millen MR, Ververs FA, Kruize AA (2014) Dendritic cells, T-cells and epithelial cells: a crucial interplay in immunopathology of primary Sj\u00f6gren\u2019s syndrome. Expert Rev Clin Immunol 10:521\u2013531","journal-title":"Expert Rev Clin Immunol"},{"key":"5429_CR64","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","volume":"78","author":"J Gao","year":"2004","unstructured":"Gao J, Morgan G, Tieu D (2004) ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj\u00f6gren\u2019s syndrome-like MRL\/lpr mice. Exp Eye Res 78:823\u2013835","journal-title":"Exp Eye Res"},{"key":"5429_CR65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.autrev.2010.05.005","volume":"9","author":"A Hansen","year":"2010","unstructured":"Hansen A, Daridon C, D\u00f6rner T (2010) What do we know about memory B cells in primary Sj\u00f6gren\u2019s syndrome? Autoimmun Rev 9:600\u2013603","journal-title":"Autoimmun Rev"},{"key":"5429_CR66","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaut.2013.06.007","volume":"45","author":"H Dooms","year":"2013","unstructured":"Dooms H (2013) Interleukin-7: fuel for the autoimmune attack. J Autoimmun 45:40\u201348. https:\/\/doi.org\/10.1016\/j.jaut.2013.06.007","journal-title":"J Autoimmun"},{"key":"5429_CR67","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1136\/annrheumdis-2016-209236","volume":"75","author":"MR Hillen","year":"2016","unstructured":"Hillen MR, Blokland SLM, Risselada AP, Bikker A, Lauwerys BR, Kruize AA, Radstake TRDJ, van Roon JAG (2016) High soluble IL-7 receptor expression in Sj\u00f6gren\u2019s syndrome identifies patients with increased immunopathology and dryness. Ann Rheum Dis 75:1735\u20131736. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209236","journal-title":"Ann Rheum Dis"},{"key":"5429_CR68","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/art.27318","volume":"62","author":"A Bikker","year":"2010","unstructured":"Bikker A, Van Woerkom JM, Kruize AA, Wenting-van Wijk M, De Jager W, Bijlsma JWJ et al (2010) Increased expression of interleukin-7 in labial salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome correlates with increased inflammation. Arthritis Rheum 62:969\u2013977. https:\/\/doi.org\/10.1002\/art.27318","journal-title":"Arthritis Rheum"},{"key":"5429_CR69","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/annrheumdis-2011-200744","volume":"71","author":"A Bikker","year":"2012","unstructured":"Bikker A, Kruize AA, Wenting M, Versnel MA, Bijlsma JWJ, Lafeber FPJG, van Roon JAG (2012) Increased interleukin (IL)-7R\u03b1 expression in salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome is restricted to T cells and correlates with IL-7 expression, lymphocyte numbers and activity. Ann Rheum Dis 71:1027\u20131033. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200744","journal-title":"Ann Rheum Dis"},{"key":"5429_CR70","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1016\/j.bbadis.2018.04.010","volume":"1864","author":"J Zhou","year":"2018","unstructured":"Zhou J, Yu Q (2018) Anti-IL-7 receptor-\u03b1 treatment ameliorates newly established Sj\u00f6gren\u2019s-like exocrinopathy in non-obese diabetic mice. Biochim Biophys Acta (BBA)-Mol Basis Dis 1864:2438\u20132447. https:\/\/doi.org\/10.1016\/j.bbadis.2018.04.010","journal-title":"Biochim Biophys Acta (BBA)-Mol Basis Dis"},{"issue":"6","key":"5429_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12822","volume":"90","author":"Q Shao","year":"2019","unstructured":"Shao Q, Gao H (2019) Progress in interleukin-2 therapy for rheumatic immune diseases by regulating the immune balance of T cells. Scand J Immunol 90(6):e12822. https:\/\/doi.org\/10.1111\/sji.12822","journal-title":"Scand J Immunol"},{"key":"5429_CR72","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/ni1263","volume":"6","author":"JD Fontenot","year":"2005","unstructured":"Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY (2005) A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6:1142\u20131151. https:\/\/doi.org\/10.1038\/ni1263","journal-title":"Nat Immunol"},{"key":"5429_CR73","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","volume":"77","author":"M Miao","year":"2018","unstructured":"Miao M, Hao Z, Guo Y, Zhang X, Zhang S, Li X et al (2018) Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 77:1838\u20131840. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213036","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"5429_CR74","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/ar1688","volume":"7","author":"EM Ruderman","year":"2005","unstructured":"Ruderman EM, Pope RM (2005) The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther 7(Suppl 2):S21\u2013S25","journal-title":"Arthritis Res Ther"},{"key":"5429_CR75","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","volume":"73","author":"PM Meiners","year":"2014","unstructured":"Meiners PM, Vissink A, Kroese FGM, Spijkervet FKL, Smitt-Kamminga NS, Abdulahad WH, Bulthuis-Kuiper J, Brouwer E, Arends S, Bootsma H (2014) Abatacept treatment reduces disease activity in early primary Sj\u00f6gren\u2019s syndrome (open-label proof of concept ASAP study). Ann Rheum Dis 73:1393\u20131396. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204653","journal-title":"Ann Rheum Dis"},{"key":"5429_CR76","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1002\/acr.22052","volume":"65","author":"S Adler","year":"2013","unstructured":"Adler S, K\u00f6rner M, F\u00f6rger F, Huscher D, Caversaccio MD, Villiger PM (2013) Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren\u2019s syndrome: a pilot study. Arthritis Care Res 65:1862\u20131868. https:\/\/doi.org\/10.1002\/acr.22052","journal-title":"Arthritis Care Res"},{"issue":"9","key":"5429_CR77","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/art.40165","volume":"69","author":"GM Verstappen","year":"2017","unstructured":"Verstappen GM, Meiners PM, Corneth OBJ, Visser A, Arends S, Abdulahad WH et al (2017) Attenuation of follicular helper T cell-dependent B cell hyperactivity by abatacept treatment in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 69(9):1850\u20131861. https:\/\/doi.org\/10.1002\/art.40165","journal-title":"Arthritis Rheum"},{"key":"5429_CR78","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","volume":"141","author":"JL Karnell","year":"2019","unstructured":"Karnell JL, Rieder SA, Ettinger R, Kolbeck R (2019) Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev 141:92\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2018.12.005","journal-title":"Adv Drug Deliv Rev"},{"key":"5429_CR79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jaut.2006.02.002","volume":"26","author":"A Goules","year":"2006","unstructured":"Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG (2006) Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 26:165\u2013171. https:\/\/doi.org\/10.1016\/j.jaut.2006.02.002","journal-title":"J Autoimmun"},{"key":"5429_CR80","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/sji.12121","volume":"79","author":"R Belkhir","year":"2014","unstructured":"Belkhir R, Gestermann N, Koutero M, Seror R, Tost J, Mariette X, Miceli-Richard C (2014) Upregulation of membrane-bound CD40L on CD4+T cells in women with primary Sj\u00f6gren\u2019s syndrome. Scand J Immunol 79:37\u201342. https:\/\/doi.org\/10.1111\/sji.12121","journal-title":"Scand J Immunol"},{"key":"5429_CR81","unstructured":"Fisher GPB, Zeher M, Ng WF, Bombardieri M, Posch M, Papas AS et al (2017) The novel anti-CD40 monoclonal antibody CFZ533 shows beneficial effects in patients with primary Sj\u00f6gren\u2019s syndrome: a phase IIa double-blind, placebo-controlled randomized trial ACR meeting abstracts. Arthritis Rheum 69(Suppl 10)"},{"key":"5429_CR82","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1136\/annrheumdis-2018-213929","volume":"78","author":"G Wieczorek","year":"2019","unstructured":"Wieczorek G, Bigaud M, Pfister S, Ceci M, McMichael K, Afatsawo C, Hamburger M, Texier C, Henry M, Cojean C, Erard M, Mamber N, Rush JS (2019) Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD\/ShiLtJ mouse model of Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 78:974\u2013978. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213929","journal-title":"Ann Rheum Dis"},{"key":"5429_CR83","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3389\/fimmu.2018.00952","volume":"9","author":"BL Walling","year":"2018","unstructured":"Walling BL, Kim M (2018) LFA-1 in T cell migration and differentiation. Front Immunol 9:952. https:\/\/doi.org\/10.3389\/fimmu.2018.00952","journal-title":"Front Immunol"},{"key":"5429_CR84","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.exer.2003.10.024","volume":"78","author":"J Gao","year":"2004","unstructured":"Gao J, Morgan G, Tieu D, Schwalb TA, Luo JY, Wheeler LA, Stern ME (2004) ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sj\u00f6gren\u2019s syndrome-like MRL\/lpr mice. Exp Eye Res 78:823\u2013835. https:\/\/doi.org\/10.1016\/j.exer.2003.10.024","journal-title":"Exp Eye Res"},{"key":"5429_CR85","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2249.1995.tb03790.x","volume":"102","author":"Y Hayashi","year":"1995","unstructured":"Hayashi Y, Haneji N, Yanagi K, Higashiyama H, Yagita H, Hamano H (1995) Prevention of adoptive transfer of murine Sj\u00f6gren\u2019s syndrome into severe combined immunodeficient (SCID) mice by antibodies against intercellular adhesion molecule-1 (ICAM-1) and lymphocyte function-associated antigen-1 (LFA-1). Clin Exp Immunol 102:360\u2013367","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"5429_CR86","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/jop.2018.0047","volume":"34","author":"R Guimaraes de Souza","year":"2018","unstructured":"Guimaraes de Souza R, Yu Z, Stern ME, Pflugfelder SC, de Paiva CS (2018) Suppression of Th1-mediated keratoconjunctivitis sicca by Lifitegrast. J Ocul Pharmacol Ther 34(7):543\u2013549. https:\/\/doi.org\/10.1089\/jop.2018.0047","journal-title":"J Ocul Pharmacol Ther"},{"key":"5429_CR87","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nri3700","volume":"14","author":"C Pitzalis","year":"2014","unstructured":"Pitzalis C, Jones GW, Bombardieri M, Jones SA (2014) Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat Rev Immunol 14:447\u2013462","journal-title":"Nat Rev Immunol"},{"key":"5429_CR88","doi-asserted-by":"publisher","first-page":"R182","DOI":"10.1186\/ar3507","volume":"13","author":"RA Fava","year":"2011","unstructured":"Fava RA, Kennedy SM, Wood SG, Bolstad AI, Bienkowska J, Papandile A, Kelly JA, Mavragani CP, Gatumu M, Skarstein K, Browning JL (2011) Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sj\u00f6gren\u2019s syndrome. Arthritis Res Ther 13:R182. https:\/\/doi.org\/10.1186\/ar3507","journal-title":"Arthritis Res Ther"},{"key":"5429_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112545","volume":"9","author":"J Bienkowska","year":"2014","unstructured":"Bienkowska J, Allaire N, Thai A, Goyal J, Plavina T, Nirula A, Weaver M, Newman C, Petri M, Beckman E, Browning JL (2014) Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. PLoS One 9:e112545. https:\/\/doi.org\/10.1371\/journal.pone.0112545","journal-title":"PLoS One"},{"issue":"9","key":"5429_CR90","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","volume":"70","author":"E William St Clair","year":"2018","unstructured":"William St Clair E, Baer AN, Wei C, Noaiseh G, Parke A, Coca A et al (2018) Clinical efficacy and safety of baminercept, a lymphotoxin \u03b2 receptor fusion protein, in primary Sj\u00f6gren\u2019s syndrome: results from a phase II randomized, double-blind. Placebo-Controlled Trial Arthritis Rheumatol 70(9):1470\u20131480","journal-title":"Placebo-Controlled Trial Arthritis Rheumatol"},{"key":"5429_CR91","doi-asserted-by":"crossref","first-page":"17609","DOI":"10.1073\/pnas.1209724109","volume":"109","author":"JC Hall","year":"2012","unstructured":"Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, Baer AN, Rosen A (2012) Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 109:17609\u201317614","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5429_CR92","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/rheumatology\/kes180","volume":"52","author":"L Quartuccio","year":"2013","unstructured":"Quartuccio L, Salvin S, Fabris M, Maset M, Pontarini E, Isola M, de Vita S (2013) BLyS upregulation in Sj\u00f6gren\u2019s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology. 52(2):276\u2013281. https:\/\/doi.org\/10.1093\/rheumatology\/kes180","journal-title":"Rheumatology."},{"issue":"12","key":"5429_CR93","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/art.40589","volume":"70","author":"J Lee","year":"2018","unstructured":"Lee J, Lee J, Kwok S-K, Baek SY, Jang SG, Hong S-M, Min J-W, Choi SS, Lee J, Cho M-L, Park S-H (2018) JAK-1 inhibition suppresses interferon-induced BAFF production in human salivary gland: potential therapeutic strategy for primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheum 70(12):2057\u20132066. https:\/\/doi.org\/10.1002\/art.40589","journal-title":"Arthritis Rheum"},{"key":"5429_CR94","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jaut.2018.02.001","volume":"91","author":"ILA Bodewes","year":"2018","unstructured":"Bodewes ILA, Huijser E, van Helden-Meeuwsen CG, Tas L, Huizinga R, Dalm VASH, van Hagen PM, Groot N, Kamphuis S, van Daele PLA, Versnel MA (2018) TBK1: a key regulator and potential treatment target for interferon positive Sj\u00f6gren\u2019s syndrome, systemic lupus erythematosus and systemic sclerosis. J Autoimmun 91:98\u2013102. https:\/\/doi.org\/10.1016\/j.jaut.2018.02.001","journal-title":"J Autoimmun"},{"issue":"Suppl 112","key":"5429_CR95","first-page":"S27","volume":"36","author":"AG Tzioufas","year":"2018","unstructured":"Tzioufas AG, Goules AV (2018) Limited efficacy of targeted treatments in Sj\u00f6gren\u2019s syndrome: why? Clin Exp Rheumatol 36(Suppl 112):S27\u2013S28","journal-title":"Clin Exp Rheumatol"},{"key":"5429_CR96","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaut.2009.10.004","volume":"34","author":"MI Christodoulou","year":"2010","unstructured":"Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM (2010) Characteristics of the minor salivary gland infiltrates in Sj\u00f6gren\u2019s syndrome. J Autoimmun 34:400\u2013407","journal-title":"J Autoimmun"},{"key":"5429_CR97","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","volume":"70","author":"E Theander","year":"2011","unstructured":"Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV (2011) Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 70:1363\u20131368","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5429_CR98","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.autrev.2016.03.004","volume":"15","author":"AV Goules","year":"2016","unstructured":"Goules AV, Tzioufas AG (2016) Primary Sj\u00f6gren\u2019s syndrome: clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev 15(7):695\u2013703","journal-title":"Autoimmun Rev"},{"issue":"2","key":"5429_CR99","first-page":"19","volume":"54","author":"PR Sada","year":"2015","unstructured":"Sada PR, Isenberg D, Ciurtin C (2015) Biologic treatment in Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 54(2):19\u201330","journal-title":"Rheumatology (Oxford)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-020-05429-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05429-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T17:21:04Z","timestamp":1696958464000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-020-05429-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":99,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5429"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05429-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"15 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}